{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Promacta&page=3", "query": { "intervention": "Promacta", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 74, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Promacta&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Promacta&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T07:40:00.882Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01147809", "title": "Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thrombocytopaenia" ], "interventions": [ { "name": "Eltrombopag olamine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2010-06", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-04-18", "last_synced_at": "2026-10-21T07:40:00.882Z", "location_count": 33, "location_summary": "Sedona, Arizona • Hot Springs, Arkansas • Rancho Cucamonga, California + 29 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Rancho Cucamonga", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147809" }, { "nct_id": "NCT00351468", "title": "EXTEND (Eltrombopag Extended Dosing Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Purpura, Thrombocytopaenic, Idiopathic" ], "interventions": [ { "name": "eltrombopag olamine (SB-497115-GR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2006-06", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-10-21T07:40:00.882Z", "location_count": 23, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 20 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00351468" }, { "nct_id": "NCT01974232", "title": "A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Immune Thrombocytopenia" ], "interventions": [], "intervention_types": [], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "19 Months to 21 Years" }, "enrollment_count": 33, "start_date": "2012-01", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2017-02-01", "last_synced_at": "2026-10-21T07:40:00.882Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01974232" }, { "nct_id": "NCT04638829", "title": "Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Immune Thrombocytopenia" ], "interventions": [ { "name": "Avatrombopag Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sobi, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-03-15", "completion_date": "2024-01-03", "has_results": true, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-10-21T07:40:00.882Z", "location_count": 20, "location_summary": "Tucson, Arizona • Whittier, California • Washington D.C., District of Columbia + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Whittier", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04638829" }, { "nct_id": "NCT01656252", "title": "Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Phase I- Cytarabine & Eltrombopag", "type": "DRUG" }, { "name": "Phase II- Sequence A", "type": "DRUG" }, { "name": "Phase II- Sequence B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2012-07", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2020-11-03", "last_synced_at": "2026-10-21T07:40:00.882Z", "location_count": 5, "location_summary": "Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more", "locations": [ { "city": "Worcester", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01656252" }, { "nct_id": "NCT02071901", "title": "Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "eltrombopag olamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 31, "start_date": "2014-08-14", "completion_date": "2019-01-06", "has_results": true, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-21T07:40:00.882Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02071901" }, { "nct_id": "NCT01328587", "title": "Eltrombopag for Moderate Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Moderate Aplastic Anemia", "Unilineage Bone Marrow Failure Disorders" ], "interventions": [ { "name": "Eltrombopag", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "2 Years to 100 Years" }, "enrollment_count": 34, "start_date": "2012-03-13", "completion_date": "2026-01-06", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-21T07:40:00.882Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01328587" }, { "nct_id": "NCT00922883", "title": "A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia, Aplastic", "Anemia, Hypoplastic", "Thrombocytopenia" ], "interventions": [ { "name": "Eltrombopag", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 43, "start_date": "2009-05-29", "completion_date": "2018-04-24", "has_results": true, "last_update_posted_date": "2020-10-20", "last_synced_at": "2026-10-21T07:40:00.882Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00922883" }, { "nct_id": "NCT02281370", "title": "Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Purpura, Thrombocytopenic, Idiopathic" ], "interventions": [ { "name": "Eltrombopag", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 39, "start_date": "2014-11-05", "completion_date": "2014-12-24", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-10-21T07:40:00.882Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02281370" }, { "nct_id": "NCT06345495", "title": "High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Splenomegaly", "Myelofibrosis" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Allogeneic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Eltrombopag", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Romiplostim", "type": "DRUG" }, { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2024-10-01", "completion_date": "2029-01-01", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-21T07:40:00.882Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06345495" } ] }